Wed, Apr 16, 2014, 5:23 AM EDT - U.S. Markets open in 4 hrs 7 mins

Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • biopharmawarrior biopharmawarrior Nov 10, 2012 4:58 PM Flag

    SNY to $5 FDA Rejects MS Application

    FDA says cancer version of ms drug is dangerous and rejected the application it looks doubtful it will ever be approved pretty scary for ms patients to be taking a chemo like cancer drug for ms and odd this is a wicked drug that could kill these people eom

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree a cancer drug being used for multiple sclerosis is strange and weird the FDA has a job to do and safety is job one i don't see it ever being approved in the USA eom

      Sentiment: Strong Sell

      • 1 Reply to glaxobioone
      • Lemtrada is a toxic drug this has no chance of being approved for MS period read the warning label scary

        WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
        Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia.

        Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days.

        Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections.

        Sentiment: Strong Sell

 
SNY
51.54-0.17(-0.33%)Apr 15 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.